Wild chamomile (Matricaria recutita L.) mouthwashes in methotrexate-induced oral mucositis

Phytomedicine ◽  
2005 ◽  
Vol 12 (1-2) ◽  
pp. 25-27 ◽  
Author(s):  
E.E. Mazokopakis ◽  
G.E. Vrentzos ◽  
J.A. Papadakis ◽  
D.E. Babalis ◽  
E.S. Ganotakis
2021 ◽  
Vol 8 (2) ◽  
pp. 133-142
Author(s):  
Juliana Borges de Lima Dantas ◽  
Tila Fortuna Costa Freire ◽  
Ana Carla Barletta Sanches ◽  
Roberto Paulo Correia de Araújo ◽  
Gabriela Botelho Martins

Author(s):  
THAÍSE PEREIRA DANTAS SAMPAIO ◽  
TATIANA STUART VIEIRA HOLMES ◽  
DANÚBIA ROBERTA DE MEDEIROS NÓBREGA ◽  
MANUELA GOUVÊA CAMPÊLO DOS SANTOS ◽  
PATRÍCIA MEIRA BENTO ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Vânia Thais Silva Gomes ◽  
Raimundo Nonato Silva Gomes ◽  
Maria Silva Gomes ◽  
Walderez Moreira Joaquim ◽  
Eliana Campêlo Lago ◽  
...  

Objective. The objective of this study was to review the effects of the Matricaria recutita (L.) in the treatment of oral mucositis. Methodology. The online search was performed in the period from June 2016 to April 2018 by means of databases LILACS (Latin American and Caribbean Center on Health Sciences Information), SciELO (Scientific Electronic Library Online), and MEDLINE (Medical Literature Analysis and Retrieval System Online). The consultation was restricted to the years 1991 to 2018 with the aim of elucidating the effects of Matricaria recutita in the treatment of oral mucositis. Results. The final sample consisted of 21 studies, of which 10 were developed in animals and 11 in humans, published from 1991 to 2017, with a total sample of 644 patients. The total number of patients treated with Matricaria included in 11 studies was 364, while in the control groups the total number was 280. In experimental studies, animal models used were rats and the sample size ranged between 36 and 105 animals submitted to the induction of oral mucositis, where 4 studies used an intraperitoneal injection of 5-fluorouracil, while 7 induced lesion in the mucosa. From the data collected, it should be noted that both studies with humans and with animals showed significant effects. In this way, there is strong evidence for the discussion on the therapy; however, it should be noted that more studies are developed in order to clarify the most appropriate protocol for the prevention and treatment of injuries. Conclusion. According to the results found in this study, Matricaria recutita appeared to be a promising alternative for the treatment of oral mucositis. However, due to the great variability in the various types of intervention, more controlled double-blind randomized clinical studies are necessary to ensure the best protocol for treating oral mucositis.


Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
G Pop ◽  
I Maior ◽  
A Militaru ◽  
C Peev ◽  
D Pop

2020 ◽  
Vol 51 (3) ◽  
pp. 172-178
Author(s):  
Natalia Bartoszewicz ◽  
Krzysztof Czyżewski ◽  
Robert Dębski ◽  
Anna Krenska ◽  
Ewa Demidowicz ◽  
...  

AbstractIntroductionOral mucositis is regarded by patients as one of the worst and debilitating complications of conditioning and hematopoietic cell transplantation (HCT). Prevention of mucositis is one of the priorities of supportive therapy during and after conditioning.ObjectivesThe primary objective of the study was the analysis of efficacy of keratinocyte growth factor (KGF, palifermin) used in prophylaxis of oral mucositis in patients undergoing allo-HCT. The secondary objectives of the study included the analysis of the influence of palifermin on clinical course of oral mucositis and early transplant outcomes, as well as analysis of the contraindications of palifermin in patients undergoing allo-HCT.Patients and methodsA total number of 253 allo-HCT performed between 2003 and 2018 in patients aged 0–19 years in a single center were analyzed. Overall, in 161 HCTs, palifermin was administered.ResultsPatients receiving KGF were transplanted earlier in the context of calendar year, and more often received ATG, mainly due to the higher rate of unrelated donor transplants. Allo-HCT patients who were administered palifermin had shorter time of mucositis (median: 9 vs. 13 days, p < 0.001), lower mucositis grade (median: 2° vs. 3°; p < 0.001), shorter period of total parenteral nutrition (median: 19 vs. 22 days; p = 0.018), and lower incidence of episodes of febrile neutropenia (median: 39.1% vs. 83.1%; p < 0.001).ConclusionsThe use of palifermin has decreased duration and severity of oral mucositis in children after allo-HCT. Palifermin is a safe and well-tolerated compound in children undergoing allo-HCT.


Sign in / Sign up

Export Citation Format

Share Document